Kyverna Therapeutics (KYTX) CFO receives new stock options and RSU grant

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. reported that its Chief Financial Officer, Marc Grasso, received new equity awards as part of his compensation. He was granted a stock option for 65,000 shares of common stock at an exercise price of $8.95 per share, expiring on March 13, 2036. He also received 10,000 shares of common stock in the form of a restricted stock unit award.

According to the vesting terms, one quarter of the restricted stock units will vest on March 13, 2027, with the remaining three quarters vesting in equal annual installments on each one-year anniversary thereafter, subject to his continued service. For the stock option, one quarter of the shares will vest on March 13, 2027, and the remaining shares will vest in equal monthly installments (1/48th each month) thereafter, also contingent on continued service to the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRASSO MARC

(Last) (First) (Middle)

C/O KYVERNA THERAPEUTICS, INC.

5980 HORTON STREET, SUITE 550

(Street)

EMERYVILLE CA 94608

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kyverna Therapeutics, Inc. [ KYTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		10,000(1)	A	$0	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$8.95	03/13/2026		A		65,000		(2)	03/13/2036	Common Stock	65,000	$0	65,000	D

Explanation of Responses:

1. Represents a restricted stock unit award of common stock and 1/4th of the shares underlying the restricted stock unit award shall vest on March 13, 2027 and an additional 1/4th of the shares underlying the restricted stock unit award shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

2. 1/4th of the shares subject to the option shall vest on March 13, 2027 and an additional 1/48th of the shares subject to the option shall vest on the same day of each month thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.

	By: /s/ Marc Grasso	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Kyverna Therapeutics (KYTX) grant to its CFO?

Kyverna Therapeutics granted CFO Marc Grasso a stock option and a restricted stock unit award. The option covers 65,000 shares at $8.95 per share, while the RSU grant represents 10,000 shares of common stock, both subject to multi-year vesting schedules.

What are the vesting terms for the KYTX CFO’s restricted stock units?

The CFO’s 10,000-share restricted stock unit award vests over four years. One quarter vests on March 13, 2027, and the remaining three quarters vest in equal annual installments on each one-year anniversary, conditioned on continued service with Kyverna Therapeutics.

How does the Kyverna Therapeutics CFO stock option vest and when does it expire?

The 65,000-share stock option vests over four years plus monthly vesting. One quarter vests on March 13, 2027, and the remaining shares vest in equal monthly 1/48th installments thereafter. The option expires on March 13, 2036, if not exercised earlier.

What is the exercise price of the Kyverna Therapeutics CFO stock option?

The stock option granted to the Kyverna Therapeutics CFO has an exercise price of $8.95 per share. This is the price at which he can purchase common shares upon vesting and exercise, subject to the option’s schedule and expiration date in 2036.

Are the KYTX CFO’s new equity awards tied to continued employment?

Yes, both the restricted stock units and stock options require continuous service. Vesting for each award occurs only if the CFO remains employed through the applicable vesting dates, aligning long-term incentives with ongoing leadership at Kyverna Therapeutics.